- Merck/Cidara Therapeutics: Acquisition of Cidara Therapeutics for 221.5 USD/share confirmed November 14, 2025
- CureVac/BioNTech: BioNTech will acquire CureVac in an all share deal with a 55% premium June 12, 2025
- Moderna: BARDA funding for phase 3 H5N1 vaccine trial terminated May 28, 2025
- Moderna: Positive phase 1/2 H5N1 vaccine interim data May 28, 2025
- CureVac/BioNTech: European Patent Office maintains amended CureVac patent EP 3 708 668 B1 challenged by BioNTech March 27, 2025
- GSK: Canada orders 500.000 H5N1 vaccine doses February 19, 2025
- Moderna: 590 million USD BARDA funding for bird flu mRNA vaccine development January 17, 2025
- Arcturus Therapeutics: Phase 1 H5N1 mRNA vaccine trial initiated January 10, 2025
- CSL: United Kingdom government orders 5 million H5 vaccine doses December 3, 2024
- Cidara Therapeutics: 105 million USD private placement funding announced November 21, 2024
- Arcturus Therapeutics: FDA clearance for Arcturus Therapeutics phase 1 bird flu vaccine trial November 11, 2024
- CSL/GSK/Sanofi: 193 million USD BARDA contracts for bird flu vaccines October 4, 2024
- Cidara Therapeutics: Workforce to be reduced by 30% to focus on CD388 September 12, 2024
- Cidara Therapeutics: Cidara Therapeutics presents at the H.C. Wainwright 26th Annual Global Investment Conference September 9, 2024
- Vir Biotechnology: Development of antibody VIR-2981 against influenza discontinued August 1, 2024
- CureVac/GSK: GSK acquires full rights to influenza vaccines from CureVac July 3, 2024
- Moderna: BARDA funding for phase 3 trial of H5N1 mRNA vaccine July 2, 2024
- Moderna/BioNTech/Pfizer/GSK/Sanofi: Moderna defends mRNA patent, appeal likely May 17, 2024
- GSK/BioNTech/Pfizer: Additional mRNA litigation April 26, 2024
- Cidara Therapeutics: Cidara Therapeutics reacquires global rights to CD388 from Johnson & Johnson, announces financing of 240 million USD, will proceed with CD388 phase 2b study in autumn 2024 April 24, 2024
News